• J. Clin. Oncol. · Dec 2014

    Randomized Controlled Trial Multicenter Study

    Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.

    • Thierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, Christian Recher, Josette Brière, Corinne Haioun, Françoise Berger, Christophe Fermé, Marie-Christine Copin, Olivier Casasnovas, Catherine Thieblemont, Tony Petrella, Karen Leroy, Gilles Salles, Bettina Fabiani, Franck Morschauser, Nicolas Mounier, Bertrand Coiffier, Fabrice Jardin, Philippe Gaulard, Jean-Philippe Jais, and Hervé Tilly.
    • Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; Catherine Thieblemont, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U728; Bettina Fabiani, AP-HP, Saint-Antoine, Paris; Christiane Copie-Bergman, Corinne Haioun, Karen Leroy, and Philippe Gaulard, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil; Christiane Copie-Bergman, Karen Leroy, and Philippe Gaulard, INSERM Unité U955 Équipe 9, Créteil; Christian Recher, Centre Hospitalier Universitaire (CHU) Purpan, Université Toulouse III Paul Sabatier, Toulouse; Françoise Berger, Gilles Salles, and Bertrand Coiffier, Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite; Christophe Fermé, Institut Gustave Roussy, Villejuif; Marie-Christine Copin and Franck Morschauser, CHU Lille, Lille; Olivier Casasnovas and Tony Petrella, CHU Dijon, Dijon; Nicolas Mounier, CHU Nice, Nice; and Fabrice Jardin and Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Rouen, France. thierry.molina@nck.aphp.fr.
    • J. Clin. Oncol. 2014 Dec 10; 32 (35): 3996-4003.

    PurposeTo determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk according to the International Prognostic Index when treated with dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) compared with standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP).Patients And MethodsUsing immunohistochemistry, expression of CD10, BCL6, MUM1, MYC, and BCL2 and coexpression of MYC/BCL2 were examined. The interaction effects between each biomarker and treatment arm on survival were studied in a restricted model and a full model incorporating clinical parameters.ResultsAmong the 379 patients analyzed in the trial, 229 tumors were evaluable for germinal center B-cell-like (GCB)/non-GCB subclassification according to the Hans algorithm. Among all the biomarkers, only the interaction between the Hans algorithm and the treatment arm was significant for progression-free survival (PFS) and overall survival (OS) in univariable (PFS, P = .04; OS, P = .01) and multivariable (PFS, P = .03; OS, P = .01) analyses. Non-GCB tumors predicted worse PFS (hazard ratio [HR], 3.21; 95% CI, 1.29 to 8.00; P = .01) and OS (HR, 6.09; 95% CI, 1.37 to 27.03; P = .02) among patients treated with R-CHOP compared with patients who received R-ACVBP, whereas there were no significant survival differences between these regimens among patients with GCB tumors.ConclusionThe survival benefit related to R-ACVBP over R-CHOP is at least partly linked to improved survival among patients with non-GCB DLBCL. Therefore, the Hans algorithm could be considered a theragnostic biomarker for selecting young patients with DLBCL who can benefit from an intensified R-ACVBP immunochemotherapy regimen.© 2014 by American Society of Clinical Oncology.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…